Compare CYD & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | PVLA |
|---|---|---|
| Founded | 1951 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | 29 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1998 | N/A |
| Metric | CYD | PVLA |
|---|---|---|
| Price | $46.34 | $144.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $60.00 | ★ $171.87 |
| AVG Volume (30 Days) | 218.3K | ★ 290.1K |
| Earning Date | 02-24-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.11 | N/A |
| Revenue Next Year | $8.67 | $104,350.18 |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.27 | $26.19 |
| 52 Week High | $61.48 | $161.38 |
| Indicator | CYD | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 59.17 |
| Support Level | $40.34 | $106.07 |
| Resistance Level | $56.55 | $156.28 |
| Average True Range (ATR) | 2.89 | 10.13 |
| MACD | -0.06 | 1.21 |
| Stochastic Oscillator | 52.59 | 65.47 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.